

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by PuraPharm Corporation Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors of the Company (the “**Board**”) proposes to seek the approval of the shareholders of the Company (the “**Shareholders**”) for certain amendments to the existing articles of association of the Company (the “**Existing Articles of Association**”) in order to bring them in line with the latest legal and regulatory requirements, including the amendments made to Appendix A1 to the Listing Rules, which became effective from 1 July 2025.

The Board wishes to amend the Existing Articles of Association for purpose of, among others:

- (i) expressly allowing voting by the Shareholders at its general meetings via electronic means;
- (ii) allowing for holding electronic and hybrid general meetings of the Company;

- (iii) removing the requirement of giving notice of availability to shareholders when a notice or document is given by way of publication on the Company and the Stock Exchange websites;
- (iv) updating procedures for electronic dissemination of documents and the acceptance of electronic instructions from Shareholders; and
- (v) making consequential and other housekeeping amendments.

The proposed amendments to the Existing Articles of Association are subject to the approval of the Shareholders by way of a special resolution at the forthcoming annual general meeting (the “AGM”) of the Company currently scheduled to be held on 27 May 2026 and will become effective upon the approval by the Shareholders at the AGM.

A circular containing, among other matters to be tabled at the AGM, details of the proposed amendments to the Existing Articles of Association together with a notice of AGM will be dispatched to the Shareholders in due course.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 30 April 2026

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Director are Mr. Leung Stephen Kwok Keung and Mr. Dong Zimeng; and the independent non-executive Directors are Dr. Hung Ting On, John, Dr. Leung Lim Kin, Simon, Prof. Tsui Lap Chee, Mr. Lee Stephen and Prof. Ng Wang Wai Charles.